This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 25.93% and 4.96%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
4 Medical Product Stocks to Buy From a Challenging Industry
by Indrajit Bandyopadhyay
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
International Growth Drives GMED Stock Amid Fierce Competition
by Zacks Equity Research
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Bruker Stock May Benefit Following Its Investment in Ridom GmbH
by Zacks Equity Research
BRKR announces a new partnership with NGS bioinformatics solution provider Ridom GmbH.
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?
by Zacks Equity Research
BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.
Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength?
by Zacks Equity Research
Insulet (PODD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
5 High-Flying Large-Cap Stocks to Buy Amid Tariff-Led Market Rout
by Nalak Das
Despite Extreme volatility, these five stocks have provided more than 4% returns past month. These are: SFM, UNH, SRAD, GME, PODD.
PODD Stock Benefits From the Launch of Omnipod 5 in Canada
by Zacks Equity Research
Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
by Zacks Equity Research
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
Insulet Gains 62.9% in a Year: What's Driving the Stock?
by Zacks Equity Research
PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
by Zacks Equity Research
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
DGX Stock Set to Benefit From New Google Cloud Partnership
by Zacks Equity Research
Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI.
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
by Zacks Equity Research
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day.
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan
by Indrajit Bandyopadhyay
Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.
Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
IART delivers better-than-expected earnings in the fourth quarter of 2024.
AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises
by Zacks Equity Research
Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
Teleflex Stock Rises on Q4 Earnings Beat, Gross Margin Crashes
by Zacks Equity Research
TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.
Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract
by Zacks Equity Research
CHE's earnings and revenues beat estimates in the fourth quarter of 2024.
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss
by Zacks Equity Research
Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.
EYE Q4 Loss Narrower Than Expected, Margins Rise, Stock Surges
by Zacks Equity Research
Continued strength in Managed Care aids National Vision's fourth-quarter 2024 performance.
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours
by Zacks Equity Research
ALC's performance is driven by robust demand for its innovative products, balanced geographic footprint and strong execution by the team.
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise
by Zacks Equity Research
Insulet's fourth-quarter results benefit from the continued high demand for Omnipod 5.